
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

72703
10.1038/s41598-024-72703-6
Article
Increased serum albumin corrected anion gap levels are associated with poor prognosis in septic patients with liver cirrhosis
Pan Zetao 1
Lin Jiancheng 1
Huo Cunyang 1
Yin Di 1
Guo Qiang Guojiang10039@163.com

12
1 https://ror.org/04n3e7v86 Department of Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu China
2 https://ror.org/051jg5p78 grid.429222.d 0000 0004 1798 0228 Department of Emergency and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu China
14 9 2024
14 9 2024
2024
14 215108 5 2024
10 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
The prognosis of septic patients with cirrhosis is worse compared to septic patients without cirrhosis. Early and accurate prognosis determination in patients with cirrhosis and sepsis is pivotal for guiding treatment decisions. The aim of this study was to investigate the association between albumin-corrected anion gap (ACAG) and clinical prognosis of patients with sepsis and cirrhosis. This study extracted data of patients with sepsis and cirrhosis from the Medical Information Mart for Intensive Care (MIMIC-IV) database. A total of 1340 patients (64.6% male) were enrolled. After confounders adjusting, elevated ACAG had a significant association with 28-day mortality (HR1.604; 95% CI 1.258–2.048; P < 0.001). Restricted cubic spline revealed that a linear relationship between ACAG and 28-day mortality (P-nonlinear = 0.089, P-overall = 0.001). According to the ROC curve analysis, the ACAG demonstrated a higher area under the curve (AUC) of 0.703 compared to AG (0.675). Kaplan–Meier analysis revealed higher 28-day mortality in high ACAG group (log-rank test, χ^2 = 175.638, P < 0.001). Furthermore, subgroup analysis showed a significant interaction between ACAG and etiology of cirrhosis (P for interaction = 0.014). Therefore, ACAG could provide clinicians with valuable insights for guiding interventions in this high-risk population.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-72703-6.

Keywords

Albumin-corrected anion gap
Sepsis
Liver cirrhosis
MIMIC-IV database
All-cause mortality
Subject terms

Diseases
Health care
Medical research
Risk factors
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Sepsis is characterized by the dysregulated host response to infection, resulting in life-threatening acute organ dysfunction1. Nowadays, due to the high morbidity and high mortality, sepsis has become a major global health challenge and economic burden2. The liver plays a vital role in regulating immune defense during the development of sepsis, while it is also a susceptible target of sepsis-related injury3. In cirrhotic patients, characterized by systemic hemodynamic alterations, gut dysbiosis, bacterial translocation, and immune dysfunction, sepsis is a common complication and a primary reason for ICU admission, contributing to a higher mortality rate and organ dysfunction compared to those without cirrhosis4,5. In recent decades, cirrhotic patients with infections have faced significant epidemiological shifts. The widespread use of quinolones for infection prophylaxis has led to a rise in gram-positive bacterial infections, while the extensive use of third-generation cephalosporins has increased infections caused by enterococci6–8. What is more, there has been a notable increase in the prevalence of multidrug-resistant and extensively drug-resistant bacteria, which are more challenging to treat and pose higher risks of unsuccessful antibiotic treatment, sepsis and mortality9,10. Currently, the prevalence of bacterial infections among cirrhotic patients hospitalized for acute decompensation ranges from 25–46%10. A large retrospective study found that infections in cirrhotic patients were associated with a fourfold increase in mortality11. Additionally, the mortality rate from sepsis in cirrhotic patients is at least twice as high as in those without cirrhosis, and the ICU mortality rate for cirrhotic patients with severe septic shock can reach an alarming 65%5. Despite the well-established management protocols for sepsis in the general population, there is a significant knowledge gap in the population of cirrhotic patients12,13. Therefore, exploring potential predictive factors correlated with adverse clinical outcomes is crucial for this special high-risk population.

The anion gap (AG) serves as a well-established indicator for evaluating both the clinical acid-base balance and the severity of the condition. Elevated AG is commonly observed in critically ill patients and is often associated with an adverse clinical prognosis14. However, as the anion gap (AG) is significantly influenced by albumin levels, hypoalbuminemia can lead to a false-negative AG result, impacting the accurate judgment of results15. Therefore, albumin-corrected anion gap (ACAG), calculated by adjusting AG based on albumin levels, was utilized to more accurately reflect the presence of unmeasured anions. The liver plays a pivotal role in maintaining acid-base balance, and liver diseases could contribute to acid-base disorders through a variety of mechanisms16. Metabolic acidosis is common in septic patients with cirrhosis due to significant hemodynamic instability, insufficient tissue perfusion, metabolic abnormalities, and hepatic dysfunction17. Previous studies have found a correlation between elevated ACAG levels and increased mortality among patients with various illnesses, including sepsis. However, there is no research exploring the connection between ACAG levels and clinical progress among septic patients with cirrhosis. Therefore, our study aimed to investigate whether ACAG could help predict the clinical outcomes in this special sepsis patient population.

Methods

Database

The MIMIC-IV database is a publicly available database for medical research, and this database provides de-identified clinical data from critical care units at Beth Israel Deaconess Medical Center. After successfully completing the online course and examination, one of the authors gained authorized access to the database and was responsible for data extraction (certification number: 48410426). Since the database has already undergone anonymization, there is no need for additional ethical approval procedures18.

Study population

We extracted data on patients diagnosed with liver cirrhosis, utilizing diagnosis codes from the International Classification of Diseases, versions 9 and 10. Inclusion criteria included (1) cirrhotic patients diagnosed with sepsis according to Sepsis 3.0 criteria (Supplemental Method)19, (2) hospitalization for 24 h or more, (3) diagnosis of sepsis between 12 h before and 24 h following admission to the ICU, (4) serum anion gap and albumin were recorded during the first day of ICU admission, (5) only the data from the first ICU admission were included.

Data extraction

In this study, demographic data, etiology of cirrhosis, vital signs, laboratory parameters, illness severity scores, comorbidities, and life-sustaining interventions were obtained from the MIMIC-IV database using Structured Query Language. Vital signs, laboratory measurements, and life-sustaining treatments extracted were limited to the initial 24 h following admission to the intensive care unit. Demographic characteristics included age and sex. Vital signals included temperature, mean arterial blood pressure, heart rate and respiratory rate. Comorbidities included ascites, hepatorenal syndrome and malignant tumor. Laboratory parameters included white blood cell, hemoglobin, platelets, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, serum creatinine (SCr), anion gap, international normalized ratio (INR), albumin, blood urea nitrogen(BUN). Illness severity scores included the Model for End-Stage Liver Disease (MELD) and Sequential Organ Failure Score (SOFA). life-sustaining interventions included vasopressors and invasive mechanical ventilation. Albumin-corrected anion gap (ACAG) was calculated as 4.4 - albumin (g/dl) * 2.5 + AG20,21. The data for vital signs and laboratory parameters were obtained using standardized and calibrated medical equipment. In addition, diagnoses of diseases and complications were obtained using ICD-9 and ICD-10 codes. The code for data extraction is available from GitHub (https://github.com/MIT-LCP/mimic-iv).

Groups and clinical outcome

The X-tile software was utilized to establish the optimal ACAG cutoff value (ACAG = 19mmol/l). Following this threshold value, patients were stratified into two groups: normal ACAG group and high ACAG group. The primary clinical outcome was the 28-day mortality after ICU admission.

Statistical analysis

Continuous variables were reported as median and interquartile range (IQR) and compared using the Mann-Whitney U-test, whereas categorical variables were expressed as counts and percentages and compared using the Chi-square test. Kaplan-Meier survival analysis was used to assess the cumulative survival rates among groups categorized by levels of ACAG, and differences between the curves were compared using the log-rank tests. To assess whether ACAG could be an independent predictor for adverse clinical outcomes in septic patients with cirrhosis, Cox regression modeling was carried out. Model 1 was unadjusted, while Model 2 was adjusted for age, gender, and type of cirrhosis. In Model 3, covariates demonstrating significance at P < 0.05 in the univariate Cox analysis (supplementary Table 1), along with those selected based on clinical experience, were included. Further, to investigated the potential nonlinear association between ACAG and 28-day mortality, a multivariate restricted cubic spline regression model with four knots was performed. To assess and compare the predictive abilities of ACAG and other indicators for adverse outcomes, receiver operating characteristic (ROC) analyses were performed. Finally, stratified analysis was applied to assess the impact of ACAG on distinct subgroups, encompassing age, sex, type of cirrhosis, MELD score, The requirement for vasopressors and invasive mechanical ventilation. All the statistical analyses were performed by SPSS software (v26.0), X-tile (V.3.6.1) and R software (v 4.3.2), P value < 0.05 was considered to be statistically significant22.

Results

Population and baseline characteristics

In total, 1340 eligible patients were enrolled for further analysis (Fig. 1). In the study, 474 patients (35.37%) were female, and the average age was 58.74 ± 7.52 years. The non-survivor group had higher values of WBC, Scr, BUN, INR, ALT, AST, Toal bilirubin, AG, ACAG, SOFA score, MELD score and higher requirement of life-supportive therapy. However, the survivor group had higher albumin levels, Hb levels than the non-survivors. In addition, survivors were generally younger and exhibited a lower incidence of ascites, hepatorenal syndrome, and malignancy, compared to non-survivors (Table 1).Fig. 1 The fowchart of patient selection.

Table 1 Baseline characteristics of the study populations.

Variables	28-day survivors	28-day non-survivors	P-Value	
Age	58.06 (50.24-65.41)	60.76 (53.63-69.68)	P<0.001	
Gender(Male)	602 (63.70%)	264 (66.84%)	P=0.274	
Etiology of cirrhosis(Alcohol)	522 (55.24%)	243 (61.52%)	P=0.034	
Laboratory measurements	
Albumin(g/dl)	2.97(2.50-3.40)	2.80 (2.40-3.20)	P<0.001	
Anion gap（mmol/l）	14.50(12.50-17.20)	17.33 (14.50-21.74)	P<0.001	
ACAG(mmol/l)	18.08(15.75-20.53)	21.50 (18.40-24.83)	P<0.001	
WBC(109/l)	8.88(6.11-12.90)	11.53 (7.91-17.57)	P<0.001	
Hemoglobin(g/l)	9.61 (8.34-10.95)	9.35 (8.12-10.70)	P=0.042	
Platelet(109/l)	97.50 (70.00-143.11)	96.33 (60.79-139.64)	P=0.100	
Creatinine (umol/l)	1.08(0.73-1.77)	1.75 (1.03-2.97)	P<0.001	
BUN(umol/l)	24.00 (15.00-41.00)	38.50 (22.04-62.96)	P<0.001	
INR	1.55 (1.35-1.93)	1.75 (1.03-2.97)	P<0.001	
ALT(U/l)	34.50 (21.00-69.11)	42.67 (26.00-85.28)	P<0.001	
AST(U/l)	69.00 (41.00-146.17)	104 (54.50-226.50)	P<0.001	
Total Bilirubin(mg/dl)	2.30 (1.21-5.10)	5.80 (2.31-15.41)	P<0.001	
Vital signs				
HR（breaths/min）	87.36 (76.93-98.37)	92.74 (81.24-104.48)	P<0.001	
MBP(mmHg)	75.13 (69.40-82.93)	70.76 (65.57-76.88)	P<0.001	
RR(breaths/min)	18.11 (15.84-20.97)	19.61 (17.13-22.64)	P<0.001	
Temperature(℃)	36.83 (36.61-37.11)	36.67 (36.40-36.94)	P<0.001	
Severity of illness	
MELD score	14.37 (9.73-20.32)	22.47 (15.78-30.23)	P<0.001	
SOFA score	8.00 (6.00-11.00)	12.00 (9.00-16.00)	P<0.001	
Comorbidities	
Ascites	438 (46.35%)	227 (57.47%)	P<0.001	
Hepatorenal syndrome	85 (8.99%)	90 (22.78%)	P<0.001	
Malignant tumour	132 (13.97%)	82 (20.76%)	P<0.001	
Organ support components	
Vasopressor	311 (32.91%)	219 (55.44%)	P<0.001	
Mechanical ventilation	401 (42.43%)	202 (51.14%)	P<0.001	
ACAG albumin-corrected anion gap; WBC white blood cell; ALT alanine aminotransferase; AST aspartate aminotransferase; BUN blood urea nitrogen; SCr serum creatinine; INR international normalized ratio; MBP mean blood pressure; RR respiratory rate; HR heart rate; SOFA Sequential Organ Failure Assessment; MELD Model for End-Stage Liver Disease.

Kaplan-Meier survival curve analysis

During the 28-day follow-up period, 395 patients (29.5%) experienced mortality. K-M curves of ACAG for 28-day mortality (Fig. 2), indicated a notably higher mortality rate in the high ACAG group (log-rank test, χ^2 = 175.638, P < 0.001).Fig. 2 The fowchart of patient selection.

Association between ACAG and all-cause mortality

To investigate the relationship between ACAG and adverse outcomes, Cox regression modeling were applied. In the unadjusted model, we observed a significant association between ACAG and 28-day mortality in septic patients with cirrhosis (HR:1.113, 95% CI 1.097–1.129, P < 0.001). Even in the fully adjusted model, ACAG persisted as an independent risk factor. When ACAG was categorized as a dichotomous variable, elevated ACAG also significantly correlated with a higher risk of 28-day mortality (Table 2). Moreover, in the multivariable restricted cubic spline model (Fig. 3), a linear association was observed between ACAG and the risk of 28-day mortality (P-nonlinear = 0.089, P-overall = 0.001).Fig. 3 Restricted cubic spline analysis of the association between ACAG and the risk of 28-day mortality in patients with sepsis and cirrhosis.

Table 2 Cox proportional hazard ratios (HR) for all-cause mortality.

Variable	Model1	Model2	Model3	
HR(95%CI)	P-value	HR(95%CI)	P-value	HR(95%CI)	P-value	
ACAG as continuous  	1.113(1.097-1.129)	P<0.001	1.114(1.098-1.131)	P<0.001	1.040(1.018-1.063)	P<0.001	
Normal ACAG	Ref		Ref		Ref		
High ACAG	3.532(2.894-4.311)	P<0.001	3.530(2.888-4.315)	P<0.001	1.604(1.258-2.048)	P<0.001	
Model 1: unadjusted; Model 2: adjusted for age, sex, etiology of cirrhosis; Model 3: adjusted for age, sex, etiology of cirrhosis, mean blood pressure, heart rate, respiratory rate, temperature, white blood cell, INR, total bilirubin, serum creatinine, blood urea nitrogen, ascites, malignant tumor, vasopressor, mechanical ventilation.

ROC curve analysis

ROC curves were performed to evaluate the predictive value of albumin, AG, ACAG, SOFA and SOFA combined with ACAG for 28-day mortality in septic patients with cirrhosis (Fig. 4 ). Our study revealed that ACAG demonstrated a superior predictive ability for 28-day mortality compared to AG (Z = 4.024, p < 0.01). Furthermore, the integration of ACAG into the SOFA score, a widely utilized tool for prognostic assessment in sepsis, resulted to a better predictive capability when compared to the original score, in septic patients with cirrhosis. (Z = 3.558, p < 0.01).Fig. 4 ROC curves for the ACAG, AG, ALB, SOFA score, and ACAG + SOFA for predicting 28-day mortality in patients with cirrhosis and sepsis.

Subgroup analysis

Subgroup analysis indicated a significant correlation between ACAG and worse prognosis in the majority of subgroups, including gender, age, MELD score, and the use of vasopressors and invasive mechanical ventilation (Fig. 5). Notably, the predictive significance of ACAG differed significantly based on the etiology of cirrhosis, showing a higher predictive value in patients with non-alcoholic cirrhosis (P for interaction = 0.014) (Fig. 5).Fig. 5 The subgroup analysis between ACAG and 28-day all-cause mortality.

Discussion

To our knowledge, this study is the first investigation into the relationship between ACAG and prognostic implications among septic patients with cirrhosis. The results indicated a significant correlation between higher ACAG levels and 28-day mortality within this special high-risk population. Importantly, even with adjustments for potential confounders, ACAG remained strongly linked to all-cause 28-day mortality and demonstrated predictive value for adverse clinical prognosis. Therefore, our study suggested that ACAG could provide clinicians with valuable insights for guiding interventions in this special high-risk population.

 To our knowledge, this study is the first investigation into the relationship between ACAG and prognostic implications among septic patients with cirrhosis. The results indicated a significant correlation between higher ACAG levels and 28-day mortality within this special high-risk population. Importantly, even with adjustments for potential confounders, ACAG remained strongly linked to all-cause 28-day mortality and demonstrated predictive value for adverse clinical prognosis. Therefore, our study suggested that ACAG could provide clinicians with valuable insights for guiding interventions in this special high-risk population.

The acid-base balance is crucial for normal bodily functions, with severe acid-base disorders often indicating a poor prognosis. Alongside the kidneys and lungs, the liver plays a vital role in maintaining acid-base equilibrium through various regulatory mechanisms17. While liver diseases frequently result in various forms of acid-base disorders, research exploring their correlation with critically ill cirrhotic patients is limited23–25. Previous studies indicated that metabolic acidosis was common among critically ill cirrhotic patient in the ICU and was associated with increased mortality. However, the reason for ICU admission can influence the clinical progression in critically ill patients with cirrhosis26. In cirrhotic patients, sepsis is a common complication and is one of the primary reasons for ICU admission among these patients. Due to the immunosuppressive state and intricate organ functional changes, this population is more susceptible to developing multi-organ dysfunction and experiencing higher mortality rates27. Furthermore, previous studies have identified sepsis as a significant independent predictor of prognosis in this cohort of patients. Hence, in this study, we focused on cirrhotic patients with sepsis, a special high-risk group and investigated the association between metabolic acid load and the clinical outcomes among these population.

AG is the difference between the concentrations of unmeasured plasma anions and cations and is widely used to assess acid-base balance in critical ill patients28.

High AG is frequently associated with increased acid production and diminished excretion of anions. In septic patients with cirrhosis, hyperlactatemia is a common acid-base disorder. The elevated lactate levels reflect the severity of tissue hypoxia, circulatory dysfunction, metabolic abnormalities, and deterioration of liver function, are linked to unfavorable clinical outcomes16. In addition, acute kidney injury (AKI) is a common complication in septic patients with cirrhosis and is also indicative of poor prognosis29. The impairment of kidney function leads to the accumulation of various acids in the body, consequently contributing to the elevation of serum AG levels. Nevertheless, albuminate constitutes an essential element of the AG, and hypoalbuminemia results in decreased plasma albuminate levels. In such scenarios, a normal AG may indicate that the decrease in albuminate levels has obscured the presence of elevated plasma acids30,31. Given the high prevalence of hypoalbuminemia in cirrhosis patients with sepsis, utilizing the ACAG could offer a more precise evaluation of acid load.

Nowadays, research has found that high ACAG was associated with adverse prognosis in various disease such as acute kidney injury, cardiovascular disease, acute pancreatitis, and so on32–35. However, there is limited research exploring the correlation between ACAG and the clinical outcomes of septic patients. Hu et al. observed a significant association between ACAG and in-hospital mortality in septic patients, with ACAG demonstrating superior predictive accuracy compared to AG and albumin36. On the contrary, Zhu et al. reported a higher AUC for serum AG compared to ACAG, indicating a slightly better predictive advantage for AG37. However, in our study which focused on patients with cirrhosis, increased ACAG was related to the increased risk of 28-day mortality. Furthermore, compared to AG, ACAG demonstrated superior predictive value for adverse clinical outcome within our special patient population. Nevertheless, given the limitations in both sensitivity and specificity of a single predictor for sepsis prognosis, scholars recommend utilizing a blend of clinical predictors to effectively detect potential adverse outcomes. In our study, we found ACAG combination with SOFA score improved the predictive value of SOFA. Hence, we proposed that the ACAG could serve as a supplementary measure in conjunction with other clinical data to enhance the precision of predicting adverse outcomes and to effectively stratify their risk in septic patients with cirrhosis.

In addition, we observed a significant interaction between the etiology of cirrhosis and ACAG, with a higher predictive value of ACAG in patients with non-alcohol-associated cirrhosis compared to those with alcohol-associated cirrhosis. This suggests that the predictive performance of ACAG varies notably depending on the underlying cause of cirrhosis, with alcohol abuse possibly playing a significant role in this variation. Chronic alcohol consumption induces significant metabolic changes, notably the increased production of ketone bodies, which are often an overlooked byproduct of alcohol metabolism but can have serious consequences38. A recent study demonstrated that ethanol treatment could upregulate proteins associated with ketogenesis, leading to a significant increase in β-hydroxybutyric acid, the primary circulating ketone body, following chronic ethanol exposure39. Additionally, alcoholic cirrhosis is frequently associated with nutritional deficiencies, particularly thiamine deficiency, which can contribute to lactic acidosis and metabolic imbalances40. These factors lead to an elevation in the ACAG, further complicating its interpretation in septic patients with alcoholic cirrhosis and potentially reducing its predictive accuracy. Previous study indicated that a higher infection risk significantly contributed to increased mortality in alcoholic cirrhosis, compared to non-alcoholic cirrhosis41. Recently, Choi et al. found that patients with alcoholic cirrhosis admitted to the ICU had worse clinical outcomes compared to those with non-alcohol-associated cirrhosis42. Nevertheless, research on the association between cirrhotic etiology and prognosis in septic patients is currently lacking. In this study, we observed higher mortality among septic patients with alcohol-associated cirrhosis, despite their younger age and lower baseline MELD scores (Supplementary Table 2). Alcohol has detrimental effects on the immune system by suppressing the functionality of immune cells and disrupting the balance of immune cell cytokines, resulting in a state of immunosuppression43. Therefore, chronic alcohol consumption may contribute to the increased severity of sepsis in patients with alcohol-associated cirrhosis. Moreover, alcohol use disorder is a common complication among patients with alcohol-associated cirrhosis. This disorder has the potential to cause harm to various organs, including the liver, cardiovascular system, and brain, consequently increasing the mortality risk in septic patients with alcohol-associated cirrhosis44. Therefore, our study emphasizes the need for heightened attention to patients with alcohol-associated cirrhosis. Furthermore, our study revealed a linear correlation between ACAG levels and 28-day mortality, suggesting that ACAG could be a reliable indicator for detecting high-risk patients with cirrhosis and sepsis. In summary, our study suggested that ACAG, an easily accessible and cost-effective indicator, holds significant predictive value for adverse outcomes in septic patients with cirrhosis.

Of course, the present study also had several limitations. Firstly, given the inherent limitations of retrospective research, it is unable to establish a definitively causal relationship. Additionally, despite the use of comprehensive statistical analyses being a strength that enhanced the credibility of our study’s findings, certain variables not controlled for in our study could still influence clinical outcomes. Additionally, the lack of external validation could impact the reliability of our results, and future studies using independent datasets are necessary to confirm these findings. Furthermore, ACAG was not dynamically monitored: only the first-day ACAG in the ICU was analyzed. Therefore, evaluating the predictive power of ACAG changes is crucial for future research.

Conclusion

High ACAG levels emerge as an independent risk factor for 28-day mortality among septic patients with cirrhosis. Integrating ACAG assessment into routine clinical practice could enhance risk stratification and guide interventions for better outcomes in this high-risk patient cohort.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Author contributions

Qiang Guo: Study design, paper review. Zetao Pan: Data extraction and analysis, paper writing. Jiancheng Lin, Cunyang Huo and Di Yin: Supervision of data processing and provision of statistical advice. All authors approved the final manuscript.

Data availability

The data utilized in this study were sourced from the MIMIC-IV database. For more information about the database, please visit: https://mimic.physionet.org/. One of the authors obtained authorized access to the database and was entrusted with the responsibility of extracting the data (certification number: 48410426). The datasets extracted and analyzed during this study can be made available by the corresponding author upon reasonable request.

Declarations

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Singer M The third international consensus definitions for sepsis and septic shock (sepsis-3) JAMA 2016 315 8 801 810 10.1001/jama.2016.0287 26903338
Singer, M. et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315(8), 801–810 (2016).26903338 10.1001/jama.2016.0287
2. Fleischmann C Assessment of global incidence and mortality of hospital-treated sepsis. current estimates and limitations Am. J. Respir Crit. Care Med. 2016 193 3 259 272 10.1164/rccm.201504-0781OC 26414292
Fleischmann, C. et al. Assessment of global incidence and mortality of hospital-treated sepsis. current estimates and limitations. Am. J. Respir Crit. Care Med. 193(3), 259–272 (2016).26414292 10.1164/rccm.201504-0781OC
3. Strnad P Liver - guardian, modifier and target of sepsis Nat. Rev. Gastroenterol. Hepatol. 2017 14 1 55 66 10.1038/nrgastro.2016.168 27924081
Strnad, P. et al. Liver - guardian, modifier and target of sepsis. Nat. Rev. Gastroenterol. Hepatol. 14(1), 55–66 (2017).27924081 10.1038/nrgastro.2016.168
4. Wong F Sepsis in cirrhosis: report on the 7th meeting of the international ascites club Gut 2005 54 5 718 725 10.1136/gut.2004.038679 15831923
Wong, F. et al. Sepsis in cirrhosis: report on the 7th meeting of the international ascites club. Gut 54(5), 718–725 (2005).15831923 10.1136/gut.2004.038679
5. Simonetto DA Management of sepsis in patients with cirrhosis: current evidence and practical approach Hepatology 2019 70 1 418 428 10.1002/hep.30412 30516866
Simonetto, D. A. et al. Management of sepsis in patients with cirrhosis: current evidence and practical approach. Hepatology 70(1), 418–428 (2019).30516866 10.1002/hep.30412
6. Fernández J Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis Hepatology 2002 35 1 140 148 10.1053/jhep.2002.30082 11786970
Fernández, J. et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 35(1), 140–148 (2002).11786970 10.1053/jhep.2002.30082
7. Piano S Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide Gastroenterology 2019 156 5 1368 1380e10 10.1053/j.gastro.2018.12.005 30552895
Piano, S. et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology 156(5), 1368-1380e10 (2019).30552895 10.1053/j.gastro.2018.12.005
8. Cheong HS Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis Clin. Infect. Dis. 2009 48 9 1230 1236 10.1086/597585 19302016
Cheong, H. S. et al. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin. Infect. Dis. 48(9), 1230–1236 (2009).19302016 10.1086/597585
9. Fernández J Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in europe J. Hepatol. 2019 70 3 398 411 10.1016/j.jhep.2018.10.027 30391380
Fernández, J. et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in europe. J. Hepatol. 70(3), 398–411 (2019).30391380 10.1016/j.jhep.2018.10.027
10. Piano S Tonon M Angeli P Changes in the epidemiology and management of bacterial infections in cirrhosis Clin. Mol. Hepatol. 2021 27 3 437 445 10.3350/cmh.2020.0329 33504138
Piano, S., Tonon, M. & Angeli, P. Changes in the epidemiology and management of bacterial infections in cirrhosis. Clin. Mol. Hepatol. 27(3), 437–445 (2021).33504138 10.3350/cmh.2020.0329
11. Arvaniti V Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis Gastroenterology 2010 139 4 1246 1256 10.1053/j.gastro.2010.06.019 20558165
Arvaniti, V. et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 139(4), 1246–1256 (2010).20558165 10.1053/j.gastro.2010.06.019
12. Baudry T Cirrhotic patients admitted to the icu with septic shock: factors predicting short and long-term outcome Shock 2019 52 4 408 413 10.1097/SHK.0000000000001282 30395082
Baudry, T. et al. Cirrhotic patients admitted to the icu with septic shock: factors predicting short and long-term outcome. Shock 52(4), 408–413 (2019).30395082 10.1097/SHK.0000000000001282
13. Son J The quick sepsis-related organ failure score has limited value for predicting adverse outcomes in sepsis patients with liver cirrhosis Korean J. Intern. Med. 2020 35 4 861 872 10.3904/kjim.2018.229 31645093
Son, J. et al. The quick sepsis-related organ failure score has limited value for predicting adverse outcomes in sepsis patients with liver cirrhosis. Korean J. Intern. Med. 35(4), 861–872 (2020).31645093 10.3904/kjim.2018.229
14. Achanti A Szerlip HM Acid-base disorders in the critically ill patient Clin. J. Am. Soc. Nephrol. 2023 18 1 102 112 35998977
Achanti, A. & Szerlip, H. M. Acid-base disorders in the critically ill patient. Clin. J. Am. Soc. Nephrol. 18(1), 102–112 (2023).35998977
15. Nanji AA Campbell DJ Pudek MR Decreased anion gap associated with hypoalbuminemia and polyclonal gammopathy Jama 1981 246 8 859 860 10.1001/jama.1981.03320080045027 6166764
Nanji, A. A., Campbell, D. J. & Pudek, M. R. Decreased anion gap associated with hypoalbuminemia and polyclonal gammopathy. Jama 246(8), 859–860 (1981).6166764 10.1001/jama.1981.03320080045027
16. Katopodis P Pappas EM Katopodis KP Acid-base abnormalities and liver dysfunction Ann. Hepatol. 2022 27 2 100675 10.1016/j.aohep.2022.100675 35074477
Katopodis, P., Pappas, E. M. & Katopodis, K. P. Acid-base abnormalities and liver dysfunction. Ann. Hepatol. 27(2), 100675 (2022).35074477 10.1016/j.aohep.2022.100675
17. Scheiner B Acid-base disorders in liver disease J. Hepatol. 2017 67 5 1062 1073 10.1016/j.jhep.2017.06.023 28684104
Scheiner, B. et al. Acid-base disorders in liver disease. J. Hepatol. 67(5), 1062–1073 (2017).28684104 10.1016/j.jhep.2017.06.023
18. Johnson AEW MIMIC-IV, a freely accessible electronic health record dataset Sci. Data 2023 10 1 1 10.1038/s41597-022-01899-x 36596836
Johnson, A. E. W. et al. MIMIC-IV, a freely accessible electronic health record dataset. Sci. Data 10(1), 1 (2023).36596836 10.1038/s41597-022-01899-x
19. Hu W Identification of indications for albumin administration in septic patients with liver cirrhosis Crit. Care 2023 27 1 300 10.1186/s13054-023-04587-3 37507790
Hu, W. et al. Identification of indications for albumin administration in septic patients with liver cirrhosis. Crit. Care 27(1), 300 (2023).37507790 10.1186/s13054-023-04587-3
20. Hatherill M Correction of the anion gap for albumin in order to detect occult tissue anions in shock Arch. Dis. Child. 2002 87 6 526 529 10.1136/adc.87.6.526 12456555
Hatherill, M. et al. Correction of the anion gap for albumin in order to detect occult tissue anions in shock. Arch. Dis. Child. 87(6), 526–529 (2002).12456555 10.1136/adc.87.6.526
21. Fenves AZ Emmett M Approach to patients with high anion gap metabolic acidosis: core curriculum 2021 Am. J. Kidney Dis. 2021 78 4 590 600 10.1053/j.ajkd.2021.02.341 34400023
Fenves, A. Z. & Emmett, M. Approach to patients with high anion gap metabolic acidosis: core curriculum 2021. Am. J. Kidney Dis. 78(4), 590–600 (2021).34400023 10.1053/j.ajkd.2021.02.341
22. DeLong ER DeLong DM Clarke-Pearson DL Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 1988 44 3 837 845 10.2307/2531595 3203132
DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3), 837–845 (1988).3203132 10.2307/2531595
23. Funk GC Acid-base disturbances in critically ill patients with cirrhosis Liver Int. 2007 27 7 901 909 10.1111/j.1478-3231.2007.01510.x 17696928
Funk, G. C. et al. Acid-base disturbances in critically ill patients with cirrhosis. Liver Int. 27(7), 901–909 (2007).17696928 10.1111/j.1478-3231.2007.01510.x
24. Drolz A Acid-base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease Ann. Intensive Care 2018 8 1 48 10.1186/s13613-018-0391-9 29675709
Drolz, A. et al. Acid-base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease. Ann. Intensive Care 8(1), 48 (2018).29675709 10.1186/s13613-018-0391-9
25. Sun DQ Metabolic acidosis in critically ill cirrhotic patients with acute kidney injury J. Clin. Transl Hepatol. 2019 7 2 112 121 31293910
Sun, D. Q. et al. Metabolic acidosis in critically ill cirrhotic patients with acute kidney injury. J. Clin. Transl Hepatol. 7(2), 112–121 (2019).31293910
26. Theocharidou E The royal free hospital score: a calibrated prognostic model for patients with cirrhosis admitted to intensive care unit. comparison with current models and clif-sofa score Am. J. Gastroenterol. 2014 109 4 554 562 10.1038/ajg.2013.466 24492755
Theocharidou, E. et al. The royal free hospital score: a calibrated prognostic model for patients with cirrhosis admitted to intensive care unit. comparison with current models and clif-sofa score. Am. J. Gastroenterol. 109(4), 554–562 (2014).24492755 10.1038/ajg.2013.466
27. Albillos A Lario M Álvarez-Mon M Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance J. Hepatol. 2014 61 6 1385 1396 10.1016/j.jhep.2014.08.010 25135860
Albillos, A., Lario, M. & Álvarez-Mon, M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J. Hepatol. 61(6), 1385–1396 (2014).25135860 10.1016/j.jhep.2014.08.010
28. Ji X Peng S The association between serum anion gap and all-cause mortality of unselected adult patients: a retrospective cohort study of > 20,000 patients J. Clin. Lab. Anal. 2023 37 1 e24818 10.1002/jcla.24818 36550640
Ji, X. & Peng, S. The association between serum anion gap and all-cause mortality of unselected adult patients: a retrospective cohort study of > 20,000 patients. J. Clin. Lab. Anal. 37(1), e24818 (2023).36550640 10.1002/jcla.24818
29. Worden A The prognostic impact of acute kidney injury recovery patterns in critically ill patients with cirrhosis Liver Transpl. 2023 29 3 246 258 10.1097/LVT.0000000000000008 36811876
Worden, A. et al. The prognostic impact of acute kidney injury recovery patterns in critically ill patients with cirrhosis. Liver Transpl. 29(3), 246–258 (2023).36811876 10.1097/LVT.0000000000000008
30. Kraut JA Madias NE Serum anion gap: its uses and limitations in clinical medicine Clin. J. Am. Soc. Nephrol. 2007 2 1 162 174 10.2215/CJN.03020906 17699401
Kraut, J. A. & Madias, N. E. Serum anion gap: its uses and limitations in clinical medicine. Clin. J. Am. Soc. Nephrol. 2(1), 162–174 (2007).17699401 10.2215/CJN.03020906
31. Jung B Diagnosis and management of metabolic acidosis: guidelines from a french expert panel Ann. Intensive Care 2019 9 1 92 10.1186/s13613-019-0563-2 31418093
Jung, B. et al. Diagnosis and management of metabolic acidosis: guidelines from a french expert panel. Ann. Intensive Care 9(1), 92 (2019).31418093 10.1186/s13613-019-0563-2
32. Zhong L The association between albumin corrected anion gap and icu mortality in acute kidney injury patients requiring continuous renal replacement therapy Intern. Emerg. Med. 2022 17 8 2315 2322 10.1007/s11739-022-03093-8 36112320
Zhong, L. et al. The association between albumin corrected anion gap and icu mortality in acute kidney injury patients requiring continuous renal replacement therapy. Intern. Emerg. Med. 17(8), 2315–2322 (2022).36112320 10.1007/s11739-022-03093-8
33. Zhao B Increased serum albumin corrected anion gap levels are associated with increased incidence of new-onset hf and poor prognosis in patients with acute myocardial infarction Clin. Chim. Acta 2023 544 117354 10.1016/j.cca.2023.117354 37076098
Zhao, B. et al. Increased serum albumin corrected anion gap levels are associated with increased incidence of new-onset hf and poor prognosis in patients with acute myocardial infarction. Clin. Chim. Acta 544, 117354 (2023).37076098 10.1016/j.cca.2023.117354
34. Li P Albumin corrected anion gap and the risk of in-hospital mortality in patients with acute pancreatitis: a retrospective cohort study J. Inflamm. Res. 2023 16 2415 2422 10.2147/JIR.S412860 37313307
Li, P. et al. Albumin corrected anion gap and the risk of in-hospital mortality in patients with acute pancreatitis: a retrospective cohort study. J. Inflamm. Res. 16, 2415–2422 (2023).37313307 10.2147/JIR.S412860
35. Sheng H The correlation between albumin-corrected anion gap and prognosis in patients with acute myocardial infarction ESC Heart Fail. 2024 11 2 826 836 10.1002/ehf2.14639 38164072
Sheng, H. et al. The correlation between albumin-corrected anion gap and prognosis in patients with acute myocardial infarction. ESC Heart Fail. 11(2), 826–836 (2024).38164072 10.1002/ehf2.14639
36. Hu T Zhang Z Jiang Y Albumin corrected anion gap for predicting in-hospital mortality among intensive care patients with sepsis: a retrospective propensity score matching analysis Clin. Chim. Acta 2021 521 272 277 10.1016/j.cca.2021.07.021 34303712
Hu, T., Zhang, Z. & Jiang, Y. Albumin corrected anion gap for predicting in-hospital mortality among intensive care patients with sepsis: a retrospective propensity score matching analysis. Clin. Chim. Acta 521, 272–277 (2021).34303712 10.1016/j.cca.2021.07.021
37. Zhu Y Serum anion gap level predicts all-cause mortality in septic patients: a retrospective study based on the mimic iii database J. Intensive Care Med. 2023 38 4 349 357 10.1177/08850666221123483 36066040
Zhu, Y. et al. Serum anion gap level predicts all-cause mortality in septic patients: a retrospective study based on the mimic iii database. J. Intensive Care Med. 38(4), 349–357 (2023).36066040 10.1177/08850666221123483
38. McGuire LC Cruickshank AM Munro PT Alcoholic ketoacidosis Emerg. Med. J. 2006 23 6 417 420 10.1136/emj.2004.017590 16714496
McGuire, L. C., Cruickshank, A. M. & Munro, P. T. Alcoholic ketoacidosis Emerg. Med. J. 23(6), 417–420 (2006).16714496 10.1136/emj.2004.017590
39. Chen, N. et al. Lysine β-hydroxybutyrylation Promotes Lipid Accumulation in Alcoholic Liver Disease. Biochem. Pharmacol., : p. 115936. (2023).
40. Schostak T Thiamine deficiency: a commonly unrecognised but easily treatable condition Postgrad. Med. J. 2023 99 1174 844 848 10.1136/pmj-2022-141972 37125640
Schostak, T. et al. Thiamine deficiency: a commonly unrecognised but easily treatable condition. Postgrad. Med. J. 99(1174), 844–848 (2023).37125640 10.1136/pmj-2022-141972
41. Rosa H Bacterial infection in cirrhotic patients and its relationship with alcohol Am. J. Gastroenterol. 2000 95 5 1290 1293 10.1111/j.1572-0241.2000.02026.x 10811341
Rosa, H. et al. Bacterial infection in cirrhotic patients and its relationship with alcohol. Am. J. Gastroenterol. 95(5), 1290–1293 (2000).10811341 10.1111/j.1572-0241.2000.02026.x
42. Choi C Relationship between etiology of cirrhosis and survival among patients hospitalized in intensive care units Mayo Clin. Proc. 2022 97 2 274 284 10.1016/j.mayocp.2021.08.025 35090753
Choi, C. et al. Relationship between etiology of cirrhosis and survival among patients hospitalized in intensive care units. Mayo Clin. Proc. 97(2), 274–284 (2022).35090753 10.1016/j.mayocp.2021.08.025
43. Ness KJ Chronic ethanol consumption decreases murine langerhans cell numbers and delays migration of langerhans cells as well as dermal dendritic cells Alcohol Clin. Exp. Res. 2008 32 4 657 668 10.1111/j.1530-0277.2007.00614.x 18241312
Ness, K. J. et al. Chronic ethanol consumption decreases murine langerhans cell numbers and delays migration of langerhans cells as well as dermal dendritic cells. Alcohol Clin. Exp. Res. 32(4), 657–668 (2008).18241312 10.1111/j.1530-0277.2007.00614.x
44. Buchanan R Sinclair JMA Alcohol use disorder and the liver Addiction 2021 116 5 1270 1278 10.1111/add.15204 32710592
Buchanan, R. & Sinclair, J. M. A. Alcohol use disorder and the liver. Addiction 116(5), 1270–1278 (2021).32710592 10.1111/add.15204
